|

Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer

RECRUITINGSponsored by Zheng Yabing
Actively Recruiting
SponsorZheng Yabing
Started2024-10-24
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving chemotherapy. The decision to use mecapegfilgrastim will be made by the treating physician as part of routine clinical care. Participants will be followed to collect information on neutropenia, febrile neutropenia, treatment-related adverse events, and chemotherapy delivery.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 18 years or older.
* Histologically confirmed advanced breast cancer, defined as locally recurrent disease not suitable for curative treatment or metastatic disease.
* First recurrence or metastasis, or documented disease progression during palliative treatment, with a planned new systemic anticancer treatment regimen.
* Estimated life expectancy of at least 3 months.
* Ability and willingness to provide written informed consent.

Exclusion Criteria:

* Early-stage breast cancer.
* Ongoing systemic anticancer treatment without a need to change to a new treatment regimen.
* Pregnant or breastfeeding women.
* Any condition or other reason that, in the investigator's judgment, makes the participant unsuitable for enrollment.

Conditions3

Breast CancerCancerChemotherapy-induced Neutropenia

Interventions2

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.